BACKGROUND AND PURPOSE
Various models of cardiovascular disease that have been used to prove the anti-fibrotic effects of serelaxin. However, whether anti-fibrotic effects of serelaxin are achieved by inhibiting inflammatory response have not been clarified. This research is intended to explore the role of serelaxin in lipopolysaccharide (LPS)-induced inflammation of cardiac fibroblasts (CFs) and elucidated the potential mechanisms.